scholarly article | Q13442814 |
P50 | author | Jorge Reis-Filho | Q23892845 |
Britta Weigelt | Q71780641 | ||
Tari A King | Q91150434 | ||
Rita Sakr | Q114337809 | ||
P2093 | author name string | James Hicks | |
Charlotte K Y Ng | |||
Catherine F Cowell | |||
P2860 | cites work | An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ | Q22000769 |
An integrated encyclopedia of DNA elements in the human genome | Q22122150 | ||
Matrix crosslinking forces tumor progression by enhancing integrin signaling | Q24646370 | ||
The microenvironment in breast cancer progression: biology and implications for treatment | Q26851314 | ||
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes | Q28270358 | ||
Genome remodelling in a basal-like breast cancer metastasis and xenograft | Q28395637 | ||
Tumour evolution inferred by single-cell sequencing | Q28646966 | ||
Inferring tumor progression from genomic heterogeneity | Q28749457 | ||
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures | Q29547700 | ||
The life history of 21 breast cancers | Q29614642 | ||
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution | Q29619477 | ||
The clonal and mutational evolution spectrum of primary triple-negative breast cancers | Q29619914 | ||
Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization | Q30673310 | ||
Molecular characterization of the tumor microenvironment in breast cancer | Q31095898 | ||
Molecular markers in ductal carcinoma in situ of the breast. | Q31135997 | ||
Gene expression profiles of human breast cancer progression | Q33186821 | ||
Gene expression profiling of the tumor microenvironment during breast cancer progression | Q33404889 | ||
Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia | Q33557658 | ||
Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. | Q33944570 | ||
Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia | Q34088976 | ||
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. | Q34206453 | ||
Absolute quantification of somatic DNA alterations in human cancer | Q34271693 | ||
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. | Q34577467 | ||
Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. | Q34694010 | ||
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. | Q35182627 | ||
The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours | Q36116099 | ||
Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast | Q36300973 | ||
Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. | Q36355592 | ||
Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell | Q36415307 | ||
Do myoepithelial cells hold the key for breast tumor progression? | Q36522966 | ||
Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression | Q36522971 | ||
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
Molecular cytogenetic analysis of 11 new breast cancer cell lines | Q36619975 | ||
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast | Q36843620 | ||
FGFR1 is amplified during the progression of in situ to invasive breast carcinoma | Q36924421 | ||
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer | Q36955125 | ||
Regulation of in situ to invasive breast carcinoma transition | Q36995611 | ||
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast | Q37097204 | ||
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas | Q37098932 | ||
A human breast cell model of preinvasive to invasive transition. | Q37143783 | ||
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection | Q37155717 | ||
LOXL2-mediated matrix remodeling in metastasis and mammary gland involution | Q37346579 | ||
Reconstruction of functionally normal and malignant human breast tissues in mice | Q37415657 | ||
Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer | Q37507568 | ||
Breast cancer precursors revisited: molecular features and progression pathways | Q37760539 | ||
Cancer genome-sequencing study design | Q38099732 | ||
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci | Q38472116 | ||
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition | Q39513776 | ||
Distinct epigenetic changes in the stromal cells of breast cancers | Q39722911 | ||
Increasingly transformed MCF-10A cells have a progressively tumor-like phenotype in three-dimensional basement membrane culture | Q39872010 | ||
The pathology of invasive breast cancerA Syllabus Derived from Findings of the National Surgical Adjuvant Breast Project (Protocol No. 4) | Q39967188 | ||
Intraductal carcinoma of the breast: Follow-up after biopsy only | Q40127804 | ||
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression | Q40291730 | ||
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer | Q41130424 | ||
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer | Q42491858 | ||
Identification of a basal-like subtype of breast ductal carcinoma in situ | Q42507010 | ||
Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast | Q42513085 | ||
Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast | Q42526325 | ||
Tumor progression in four mammary epithelial cell lines derived from the same patient | Q42809631 | ||
Human 21T breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and show stage-specific gene expression patterns | Q42814075 | ||
Gene amplification in ductal carcinoma in situ of the breast | Q45723421 | ||
The human myoepithelial cell is a natural tumor suppressor | Q46183897 | ||
MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. | Q52832877 | ||
Intratumor heterogeneity: seeing the wood for the trees. | Q53097757 | ||
Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. | Q53262835 | ||
Heterogeneous chromosomal aberrations in intraductal breast lesions adjacent to invasive carcinoma. | Q53405516 | ||
Promoter CpG island hypermethylation during breast cancer progression. | Q53449089 | ||
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. | Q53568961 | ||
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. | Q53597732 | ||
Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. | Q54757490 | ||
Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. | Q55223470 | ||
Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma | Q59573887 | ||
Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression | Q63372138 | ||
On the origin and progression of ductal carcinoma in the human breast | Q69998182 | ||
Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy | Q71079558 | ||
Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast | Q71767613 | ||
Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes | Q73341667 | ||
Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study | Q73680610 | ||
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways | Q77976506 | ||
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast | Q78656284 | ||
Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization | Q79661456 | ||
The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up | Q81731306 | ||
Genetic heterogeneity and cancer drug resistance | Q83791245 | ||
P433 | issue | 5 | |
P921 | main subject | ductal carcinoma | Q5311598 |
breast cancer | Q128581 | ||
P304 | page(s) | 859-869 | |
P577 | publication date | 2013-07-12 | |
P1433 | published in | Molecular Oncology | Q2190736 |
P1476 | title | Progression from ductal carcinoma in situ to invasive breast cancer: revisited | |
P478 | volume | 7 |
Q92260652 | A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk |
Q92257886 | APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer |
Q90370810 | ATM-dependent activation of SIM2s regulates homologous recombination and epithelial-mesenchymal transition |
Q28083103 | Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast |
Q38612319 | Best practices for multidisciplinary integration of a DCIS genomic assay into clinical practice |
Q38785162 | Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features? |
Q38764251 | Catalog of genetic progression of human cancers: breast cancer |
Q38388286 | Caveolae and signalling in cancer |
Q36087440 | Cellular senescence and autophagy of myoepithelial cells are involved in the progression of in situ areas of carcinoma ex-pleomorphic adenoma to invasive carcinoma. An in vitro model |
Q92596378 | Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ |
Q97538221 | Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer |
Q96642228 | Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions |
Q41641225 | Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score |
Q38333149 | Current management of lesions associated with an increased risk of breast cancer |
Q90467694 | Discriminating the earliest stages of mammary carcinoma using myoepithelial and proliferative markers |
Q58595841 | Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing |
Q90184743 | Ductal Carcinoma in Situ: Current Concepts in Biology, Imaging, and Treatment |
Q38696796 | Ductal carcinoma in situ - update on risk assessment and management |
Q91723932 | Ductal carcinoma in situ: to treat or not to treat, that is the question |
Q27025321 | Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment |
Q92480700 | Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer |
Q63633881 | Ectopic expression of PLC‐β2 in non‐invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR‐146a |
Q47821353 | Epithelial-mesenchymal transition inducer Snail1 and invasive potential of intraductal breast cancer. |
Q58693482 | Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats |
Q39296522 | Evolution of Premalignant Disease. |
Q38746332 | Family history and risk of breast cancer: an analysis accounting for family structure |
Q39056693 | Force-dependent breaching of the basement membrane |
Q39012815 | Genome evolution in ductal carcinoma in situ: invasion of the clones |
Q89267498 | Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma |
Q55554673 | Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. |
Q37219845 | Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ (DCIS) Suggests Metabolic Heterogeneity |
Q47169465 | Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. |
Q38757831 | Harnessing 3D models of mammary epithelial morphogenesis: An off the beaten path approach to identify candidate biomarkers of early stage breast cancer |
Q52894184 | Histogram analysis of volume-based apparent diffusion coefficient in breast cancer. |
Q36902060 | How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis? |
Q90220716 | Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS) |
Q94471981 | Identifying opportunities to support patient-centred care for ductal carcinoma in situ: qualitative interviews with clinicians |
Q39013710 | Identifying progression predictors of breast ductal carcinoma in situ. |
Q87070703 | Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast |
Q92001842 | Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ |
Q90593569 | In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ |
Q56999072 | Integrated analysis of dysregulated lncRNA expression in breast cancer cell identified by RNA-seq study |
Q33618236 | Interactions between exosomes from breast cancer cells and primary mammary epithelial cells leads to generation of reactive oxygen species which induce DNA damage response, stabilization of p53 and autophagy in epithelial cells |
Q57159647 | Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence |
Q55251624 | Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells. |
Q91795301 | MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene |
Q48221533 | Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology |
Q34576614 | Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers |
Q47200971 | Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing |
Q92624732 | Nanoemulsions Enhance in vitro Transpapillary Diffusion of Model Fluorescent Dye Nile Red |
Q35693355 | Non-coding RNAs derived from an alternatively spliced REST transcript (REST-003) regulate breast cancer invasiveness |
Q98178015 | Novel role for the Golgi membrane protein TMEM165 in control of migration and invasion for breast carcinoma |
Q49988885 | On the trail of invasive cells in breast cancer |
Q33587930 | PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma |
Q61808697 | Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea |
Q29994686 | Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ |
Q38888197 | Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. |
Q57032491 | Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing |
Q59799842 | Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells |
Q36317741 | Role of multi-mode ultrasound in the diagnosis of level 4 BI-RADS breast lesions and Logistic regression model |
Q38261363 | Sex, eyes, and vision: male/female distinctions in ophthalmic disorders |
Q92340124 | TGF-β1 stimulates epithelial-mesenchymal transition and cancer-associated myoepithelial cell during the progression from in situ to invasive breast cancer |
Q90582974 | The Importance of Risk-Reducing Prophylactic Mastectomy in Breast Cancer (BRCA) Carriers: A Case Report |
Q37705673 | The effects of turmeric (curcumin) on tumor suppressor protein (p53) and estrogen receptor (ERα) in breast cancer cells |
Q35660389 | The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study |
Q33736524 | The regulation of steroid receptors by epigallocatechin-3-gallate in breast cancer cells |
Q37635620 | The regulation of tumor suppressor protein, p53, and estrogen receptor (ERα) by resveratrol in breast cancer cells |
Q37371138 | Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model |
Q34023603 | Towards optimal treatment of ductal carcinoma in situ |
Q36447987 | Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ |
Q90394997 | Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile |
Q38703282 | Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGFβ signaling |
Q26785362 | Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression |
Q42653642 | Vaccines and early breast cancer |
Q90710834 | Whole-Exome Sequencing Analysis of the Progression from Non-Low Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma |
Q38884681 | p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. |
Search more.